Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

References

• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med201318734736522878278
   PubMed Web of Science ®Google Scholar
• TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114916321034447
   PubMed Web of Science ®Google Scholar
• KeatingGMTiotropium bromide inhalation power: a review of its use in the management of chronic obstructive pulmonary diseaseDrugs20127227330022217233
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-agonists therapy in lung diseaseAm J Respir Crit Care Med201318769069623348973
   PubMed Web of Science ®Google Scholar
• BeehKMBeierJThe short, the long, and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseAdv Ther20102715015920411368
   PubMed Web of Science ®Google Scholar
• MalerbaMRadaeliAMorjariaJBTherapeutic potential for novel ultra long acting beta2-agonists in the management of COPD: biological and pharmacological aspectsDrug Discov Today20121749650422119310
   PubMed Web of Science ®Google Scholar
• CecereLMSlatoreCGUmanJEAdherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD)COPD2012925125822497533
   PubMedGoogle Scholar
• GlaabTVogelmeierCBuhlROutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsRespir Res201011798520565728
   PubMed Web of Science ®Google Scholar
• BarnesPPocockSJMagnussenHIntegrating indacaterol dose selection in a clinical study in COPD using an adaptive and seamless designPulm Pharmacol201023165171
   Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBINDORSE Study InvestigatorsLong-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest2011140687521349928
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNINLIGHT Study GroupEfficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med201010112020211002
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRVinckenWPuente-MaestuLSwalesJLawrenceDthe INABLE Study GroupEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med20111051030103621498063
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSthe INLIGHT-2 Study InvestigatorsOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J20113727327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCINSIST Study GroupIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med201110571972621367594
   PubMed Web of Science ®Google Scholar
• LaforceCAumannJParrenoLDIqbalAYoungDOwenRINTEGRAL Study InvestigatorsSustained 24-hour efficacy of once-daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, cross-over studyPulm Pharmacol Ther20112416216820619353
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlRINVOLVE Study InvestigatorsEfficacy of a new once-daily inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax20106547347920522841
   PubMed Web of Science ®Google Scholar
• VogelmeierCRamos-BarbonDJackDPiggottSOwenRHigginsMINTIME Study InvestigatorsIndacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumRespir Res20101113513920920365
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJINHANCE study investigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med201018215516220463178
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCINTENSITY Study GroupBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J20113879780321622587
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• RennardSBantjeTCentanniSA dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonRespir Med20081021033104418479895
   PubMed Web of Science ®Google Scholar
• KhindriSSaboRHarrisSWoessnerRJenningsSDrollmannAFCardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT studyBMC Pulm Med2011113121615886
   PubMed Web of Science ®Google Scholar
• WorthHChungKFFelserJMHuHRueeggPCardio- and cerebrovascular safety of indacaterol versus formoterol, salmeterol, tiotropium and placebo in COPDRespir Med201110557157921227674
   PubMed Web of Science ®Google Scholar
• PascoeSReynoldsCPleskowWSafety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPDInt J Clin Pharmacol Ther20114915316121255532
   PubMed Web of Science ®Google Scholar
• CutlerDMEverettWThinking outside the pillbox – medication adherence as a priority for health care reformN Engl J Med20103621553155520375400
   PubMed Web of Science ®Google Scholar
• JonesPWBarnesNVogelmeierCLawrenceDKramerBEfficacy of indacaterol in the treatment of patients with COPDPrim Care Respir J20112038038821785813
   PubMedGoogle Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax20086383183818728206
   PubMed Web of Science ®Google Scholar
• IncorvaiaCRiario-SforzaGGEffect of patient education on adherence to drug treatment for chronic obstructive pulmonary diseaseAnn Thorac Med2011624224321977074
   PubMed Web of Science ®Google Scholar
• RibeiroMChapmanKRComparative efficacy of indacaterol in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2012714515222419862
   PubMed Web of Science ®Google Scholar
• ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem2010534522453020462258
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest201214211912722241764
   PubMed Web of Science ®Google Scholar
• KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPloS One20127e5071623284643
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDRespir Med201310756056923352226
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialRespir Med201310755055923332861
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther2010334536220371707
   PubMed Web of Science ®Google Scholar
• CasarosaPKolakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther201133760060921357659
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel 2-agonist olodaterol in COPDPulm Pharmacol Ther20112466667221839850
   PubMed Web of Science ®Google Scholar
• KikkawaHIsogayaMNagaoTKuroseHThe role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005Mol Pharmacol1998531281349443940
   PubMed Web of Science ®Google Scholar
• RosethorneEMTurnerRJFairhurstRACharltonSJEfficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonistsNaunyn Schmiedebergs Arch Pharmacol201038225526320694793
   PubMed Web of Science ®Google Scholar
• VossHPShukrulaSWuTSDonnelDBastAA functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005J Pharmacol Exp Ther19942713863897965739
   PubMed Web of Science ®Google Scholar
• BatemanEDCarmoterol – safety and tolerability of a long-acting β2 agonist in patients with COPDProc Am Thorac Soc20085A653
   Google Scholar
• VogelmeierCMagnussenHLaForceCOwenRKramerBProfiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary diseaseTher Adv Respir Dis2011534535721719531
   PubMedGoogle Scholar